Podcasts about bioscience

Colossal Laboratories & Biosciences has been in the news quite frequently in recent years. If you've heard the term "de-extinction" it was likely referring to their work. Colossal's Chief Animal Officer and Executive Director of the Colossal Foundation Matt James joins us in studio this week. We talk about Colossal's origin and growth into a [...]

Aron Knickerbocker, President and CEO of Aulos Bioscience,  is on a mission to extend the lives of cancer patients through safer and more effective immunotherapy using AI and machine learning to accelerate drug discovery and optimization. The company's lead drug candidate is an antibody that was designed using AI to harness the power of interleukin-2 to activate the immune system against tumors.  The advantages of AU-007 over previous IL-2 therapies include the ability to selectively activate tumor-fighting immune cells while avoiding toxicity due to vascular leakage. Current trials are underway in advanced melanoma and non-small cell lung cancer, which are showing the potential for durable responses and immune memory. Aron explains, "So Aulos has really been founded to carry out a mission to extend the lives of patients with innovative, safe, and ultimately effective cancer immunotherapy. And you mentioned IL-2, which is the naturally occurring protein that we're seeking to harness and redirect in productive ways to help the patients. And this has really been kind of a driver for me over the years, wanting to improve on cancer patient care. This is a company with an important mission and a great team, and our program is really interesting. It's harnessing IL-2 in such a way that it sends it to the cells that are capable of attacking the tumor and killing the tumor cells, and keeps it away from the cells that suppress the immune response. It's really kind of using a double-edged sword in a productive way to help patients with cancer." "So this is the first antibody to go into human clinical trials. It was designed in part by leveraging an AI platform, as you noted. And that platform was created by our collaborators at Biologic Design. They're the company that created this molecule. And what biologic design does is essentially using an AI system that has machine learning algorithms that drive it. It mimics what the immune system does normally. So when we get sick and we need to make antibodies to something, our immune system says, Do I already have something that will kind of bind to the target or the virus or whatever it's trying to hit? And then it will optimize that. It will go through a process of rapid change. And what the AI system and the machine learning algorithms that have been trained on millions of antibodies in the targets to which they bind do is recognize patterns much like an AI chatbot might recognize language patterns." #AulosBio #Antibodies #MedAi #AI #IL2 #Onocology #Cancer #NSCLC #AdvancedCutaneousMelanoma #DrugDiscovery #BiologicDesign #Tregs aulosbio.com Download the transcript here

Aron Knickerbocker, President and CEO of Aulos Bioscience,  is on a mission to extend the lives of cancer patients through safer and more effective immunotherapy using AI and machine learning to accelerate drug discovery and optimization. The company's lead drug candidate is an antibody that was designed using AI to harness the power of interleukin-2 to activate the immune system against tumors.  The advantages of AU-007 over previous IL-2 therapies include the ability to selectively activate tumor-fighting immune cells while avoiding toxicity due to vascular leakage. Current trials are underway in advanced melanoma and non-small cell lung cancer, which are showing the potential for durable responses and immune memory. Aron explains, "So Aulos has really been founded to carry out a mission to extend the lives of patients with innovative, safe, and ultimately effective cancer immunotherapy. And you mentioned IL-2, which is the naturally occurring protein that we're seeking to harness and redirect in productive ways to help the patients. And this has really been kind of a driver for me over the years, wanting to improve on cancer patient care. This is a company with an important mission and a great team, and our program is really interesting. It's harnessing IL-2 in such a way that it sends it to the cells that are capable of attacking the tumor and killing the tumor cells, and keeps it away from the cells that suppress the immune response. It's really kind of using a double-edged sword in a productive way to help patients with cancer." "So this is the first antibody to go into human clinical trials. It was designed in part by leveraging an AI platform, as you noted. And that platform was created by our collaborators at Biologic Design. They're the company that created this molecule. And what biologic design does is essentially using an AI system that has machine learning algorithms that drive it. It mimics what the immune system does normally. So when we get sick and we need to make antibodies to something, our immune system says, Do I already have something that will kind of bind to the target or the virus or whatever it's trying to hit? And then it will optimize that. It will go through a process of rapid change. And what the AI system and the machine learning algorithms that have been trained on millions of antibodies in the targets to which they bind do is recognize patterns much like an AI chatbot might recognize language patterns." #AulosBio #Antibodies #MedAi #AI #IL2 #Onocology #Cancer #NSCLC #AdvancedCutaneousMelanoma #DrugDiscovery #BiologicDesign #Tregs aulosbio.com Listen to the podcast here

For this episode of BioScience Talks, we're joined by two guests, Brittany Mason, a Data Management Analyst at the University of Florida, and Corey Callaghan, Assistant Professor at the University of Florida in the Department of Wildlife Ecology and Conservation. They were here to discuss their recent BioScience article, iNaturalist Accelerates Biodiversity Research.  

Die Themen in den Wissensnachrichten: +++ Plastik ist nicht erst als Müll schädlich, sondern schon vorher +++ Seeleoparden-Männchen singen eine Art Kinderlied +++ KI-Training durch menschliches Feedback könnte für mehr Falschinfos sorgen +++**********Weiterführende Quellen zu dieser Folge:The Lancet Countdown on health and plastics, The Lancet, 03.08.2025Leopard seal song patterns have similar predictability to nursery rhymes, Scientific Reports, 31.07.2025Machine Bullshit: Characterizing the Emergent Disregard for Truth in Large Language Models, arXiv, 10.07.2025Fermented fruits: scrumping, sharing, and the origin of feasting, BioScience, 31.07.2025Sun, sea and sexual violence: the political economy of party tourism, International Affairs, 01.07.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

***For 20% off your Solstice order, use code ABOVEANDBEYOND*****A note from Dr. Lewellis: We encountered a number of recording difficulties during this episode, which resulted in a mild echo and some transitions that can be hard to follow. My wonderful editing team did an excellent job cleaning and patching things up, but I do want my audience to be aware of it. I apologize in advance, and thanks as always for listening!**Episode 058 | Brett  Ozanich, DO, FAAD is a Board Certified Dermatologist and Micrographic Dermatologic Surgeon at Epiphany Dermatology in El Paso, Texas. He performs approximately 1500 Mohs cases per year as well as providing medical and cosmetic dermatology services.  In April of 2024, Brett and his wife, an anesthesiologist, conceptualized a skin-focused line of beverages that they named Solstice. In 2025, Solstice came to market with a glow-up in a can. Packed with powerhouse ingredients like polypodium leucotomos, zinc, niacinamide, and vitamins A, C, D, Solstice works in harmony with sunscreen and other sun protective measures to shield your skin from the inside out. Whether you're starting your day with the vibrant “Let's Glo” or winding down with the relaxing “After Hours,” every sip is designed to help you feel radiant and ready to shine.Dr. Ozanich received his Doctor of Osteopathic Medicine at Kansas City University of Medicine & Biosciences and completed Dermatology Residency at San Antonio Military Medical Center. He is a fellow of the American Academy of Dermatology (AAD) and the American Society of Mohs Surgery (ASMS), as well as an active member of the American Society of Dermatologic Surgery (ASDS), the Texas Dermatologic Society (TDS), and the Texas Medical Association (TMA). He is actively involved in medical student and physician-assistant student education as well as research/clinical trials.Dr. Lewellis does not have an ownership stake in Solstice to declare, and Solstice did not provide financial or other support for this episode, which was recorded on March 21st, 2025.Connect with and learn from Dr. Ozanich and SolsticeDr. Brett Ozanich at Epiphany DermatologySolstice — Drink Up. Glo Up.Solstice on InstagramMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.Above & Beyond DermatologyNutrafol -- special pricing and physician exclusive productsNeoGenesis -- my favorite source of stem cell released molecules for skin/hairSilagen.biz -- physician dispensed scar refinement products delivered to your door (use practice code 1206240832P)NewsletterLinkedInFacebookDr. Lewellis on InstagramAbove & Beyond Dermatology on InstagramYouTubeTikTokTwitter/XChange Your Mind, Change Your LifeSoMeDocs (Doctors on Social Media)Pippa!

 James Lazarovits is the CEO and Co-Founder of Archon Biosciences, a leader at the intersection of materials engineering and artificial intelligence. James brings over 15 years of experience building, mentoring, and investing in deep tech startups across AI, software, hardware, and robotics. Before founding Archon, James was at the forefront of AI-driven computational protein design as a post-doctoral fellow and later research faculty at the Institute for Protein Design at the University of Washington, under the direction of 2024 Nobel Laureate, David Baker. There, he contributed to pioneering methods that integrate machine learning and molecular engineering to create next-gen therapeutic proteins. Jamie earned his PhD in nanotechnology engineering from the University of Toronto where he worked under Nanomedicine expert, Dr. Warren Chan. His doctoral work focused on overcoming biological delivery barriers, using nano materials and deep learning, laying the groundwork for his later contributions to rational protein design. See omnystudio.com/listener for privacy information.

On today's episode, hear from Jose Ramirez, director of agronomy at Impello Biosciences and speaker at the 2025 Crop Consultant Conference, about his upcoming session in September on the role of silicon in plant nutrition and abiotic stress.Supporting the People who Support AgricultureThank you to this month's sponsors who makes it possible to get you your daily news. Please feel free to visit their website.2025 Crop Consultant Conference - https://myaglife.com/crop-consultant-conference/

In this episode of Assurance in Action, host Dr. Dhanashree Bhelose, Global Head for Biosciences at Intertek, continues our biodegradability series with a deep dive into synthetic textiles. She's joined by Andrea Ferris, CEO and Co-Founder of Intrinsic Advanced Materials, to discuss CiCLO® — an innovative technology that makes polyester biodegradable without compromising performance. Together, they explore the science, market trends, and future of sustainable textiles, as well as the urgent need to address microplastic pollution.Discover how CiCLO® is reshaping the textile industry and why responsible innovation is key to closing the loop.Follow us on- Intertek's Assurance In Action || Twitter || LinkedIn.

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's upcoming clinical trial application in Europe for its MASH (metabolic dysfunction-associated steatohepatitis) therapy, GF-1002. Leire explained that Genflow is prioritising the European Medicines Agency over the FDA as it seeks clinical trial authorisation (CTA) for its GF-1002 programme. He emphasised the importance of this milestone in building company value, stating: “To have proof of efficacy in humans is super important for us to move as fast as possible to clinical trial authorisation.” The company is working with Belgian-based CDMO Exothera on the CMC part of the filing, and Leire said results so far have exceeded expectations. He also highlighted the dual-CRO strategy involving Physiogenex and Accelera to address both early and late-stage MASH models. This approach aims to provide flexibility when engaging with regulators about the most effective path forward. In a second update, Leire said the protocol for Genflow's GF-1004 dog trial has been amended. The changes relate to the infusion rate of the gene therapy, intended to ensure consistency and future usability by private veterinarians. This is seen as a key step toward a potential partnership with an animal health company, which would bring non-dilutive funding to the business. Leire also mentioned supportive market tailwinds from upcoming FCA regulatory changes. For more biotech updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and hit the notification bell to stay informed. #GenflowBiosciences #MASH #BiotechNews #GeneTherapy #ClinicalTrials #GF1002 #PharmaUpdates #AnimalHealth #NonDilutiveFunding #BiotechInvesting #GLP1 #MetabolicDisease #ProactiveInvestors

What if you could transform your business by embracing cutting-edge technology and innovation? Join us for an eye-opening conversation with Jay Kulkarni, CEO of Theorem, who shares his remarkable journey of adapting to the fast-paced world of digital innovation. With over two decades of experience, Jay provides a masterclass in future-proofing your business, diving into the pivotal role of automation and AI in redefining business models for long-term success. From the revolutionary solution Upward to the intricacies of video commerce, discover how technology can streamline operations and create lasting value. Explore the profound impact of AI across industries as we unravel its efficiency in transforming sectors like pharma and media. Jay articulates the significance of identifying and alleviating friction points in advertising sales through technological advancements. But the conversation doesn't stop there. We also discuss the essential skills entrepreneurs need as their ventures grow, the strategic importance of investing in team development, and the art of risk management. Through stories of resilience during economic challenges, learn about the importance of playing the long game and nurturing internal talent to thrive in an ever-evolving market. Timestamps 00:00:00 - Introduction and Welcome to Business Legacy Podcast   00:00:04 - Conversation with Jay Kulkarni, CEO of Theorem   00:00:20 - Jay's Two-Decade Career in the Digital Space   00:01:00 - Importance of Adapting Business Models with Technological Change   00:02:30 - Integration of Automation and AI in Business Operations   00:04:03 - The Transformative Impact of AI in Various Industries   00:05:00 - AI's Role in Revolutionizing Processes and Creating New Value   00:06:30 - Discussion on Robotic Process Automation and Language Models   00:07:45 - Applications of AI in Pharma and Biosciences   00:09:00 - Projects Like Upward and Video Commerce Initiatives   00:10:30 - Friction Points in Media Advertising Sales   00:11:45 - Evolving Skills Needed for Entrepreneurs   00:13:31 - Evolution and Adaptation Strategies for Long-Term Success   00:14:45 - Emphasizing the Importance of Cross-Skilling and Up-Skilling   00:16:00 - Reflections on Economic Hardships and Risk Management   00:17:15 - Importance of Attitude and Soft Skills in Hiring   00:18:30 - Fostering Resourcefulness in Teams   00:19:45 - Navigating the Challenges of Legacy Business Owners   00:21:00 - Investing in Teams and Creating New Career Opportunities   00:22:15 - Tough Decisions During Economic Downturns   00:23:30 - Leadership Style and Communication Strategies   00:24:45 - Evolution from Web 1.0 to Web 3.0   00:26:00 - The Legacy of Value Creation and Servant Leadership   00:27:15 - Stories of Former Employees and Their Successes   00:28:30 - Conclusion and Final Thoughts from Jay Kulkarni   00:29:45 - Closing Remarks and Where to Find More Information About Theorem   Episode Resources: Connect with Jay here for more information: https://www.linkedin.com/in/jay-kulkarni-theorem/ Legacy Podcast: For more information about the Legacy Podcast and its co-hosts, visit businesslegacypodcast.com. Leave a Review: If you enjoyed the episode, leave a review and rating on your preferred podcast platform. For more information: Visit businesslegacypodcast.com to access the shownotes and additional resources on the episode.

For this episode of BioScience Talks, we were joined by Dr. Kristy Ferraro, who is a Banting Postdoctoral Fellow at Memorial University in Newfoundland and Labrador, and Adam Meyer, a PhD candidate in the Ecosystem Ecology Lab, also at Memorial University. They were here to talk about their recent article in BioScience, "Beyond hero and villain narratives in ecology and conservation science," in which they discuss storytelling and narratives in science writing—and explain which approaches work best.

He's not calling it retirement. But after a successful career as CBIA senior counsel and executive director of the Connecticut Bioscience Growth Council, Paul Pescatello is ready for “a little bit of rebalancing.” Pescatello joined the CBIA BizCast to reflect on his career and the state of the biotech industry. Pescatello started his career as a banking and insurance regulatory lawyer with Shipman and Goodwin. “They needed somebody to do some lobbying to start a new bank,” he said. “There was actually legislation needed to make it happen. “So, I volunteered and that's sort of how I learned how to lobby in Connecticut.” Pescatello's interest in the bioscience and pharmaceutical industry arose from a family crisis. “My oldest brother, who I was really close to, came down with glioblastoma, which is a really, really terrible form of brain cancer,” he said. “I think when something like that happens to you or to somebody you know really well— you want to do something. “You want to channel your energies into something that would help this person or help people in the future.” He said being involved in his brother's care and treatment drew him to the research that pharmaceutical companies were doing. “I really love the industry. It was such a fascinating industry,” he said. Pescatello started doing pro bono work in the area and ran a bioscience advocacy organization. He joined CBIA in 2014, and started managing the Connecticut Bioscience Growth Council. Pescatello said his goal was to educate people that the innovation and research done by the pharmaceutical industry was key to solving the healthcare crisis. “People here at CBIA have heard me talk about it over and over again—as costly as some drugs are, they really are a cost saver to the overall health system,” he said. Pescatello said that a major expense in the cost of drugs is the vast amount of research and development that goes into the process. “It's just hard to wrap your mind around the really unique research and development arc of bringing a drug from idea to FDA approved products,” Pescatello said. It takes $2.7 billion and about 10-12 years to bring a drug from idea to product. “When legislators ask, ‘why are drug prices so high here?' It's true, we really do pay the world's R&D.” Pescatello credited the buy-in from legislatures and administrations to understand the importance the industry carries in the state. That buy-in has led to Connecticut being at the forefront of research and development tax credits for biotech companies. “They're spending tons and tons of money, but they have no income coming in,” Pescatello said. “So those research and development tax credits—they can carry them forward into the future.” He said it's critical for the state to stay competitive to support and grow the industry. “Things like the research and development tax credits—other states have copied that,” he said. “We have to keep in the game on that.” Pescatello said it's been satisfying to see the growth of the industry in Connecticut. “I drive a lot of satisfaction from the range of companies that are here and the range of products that come out of Connecticut,” he said. “We should all really take a victory lap for how big the industry is in Connecticut and how sustainable it is.” As he “rebalances,” Pescatello said he's looking forward to spending more time with his five grandchildren. But he said he plans to continue his advocacy for the bioscience industry. “I love the industry,” he said. “I really care about it in terms of its effect on all of us and on patients and disease—understanding the mechanisms of disease and finding treatments and cures for disease.” ________________________________________ The CBIA BizCast is made possible through the generous support of Google. Please rate, review, and subscribe to the BizCast wherever you get your podcasts—we appreciate your support!

Die Themen in den Wissensnachrichten: +++ Erstmals hat ein KI-gestützter Roboter ohne menschliche Hilfe eine Gallenblase operiert +++ Haushalts-Aufgaben bei Paaren noch ziemlich ungleich +++ Wie sich eine Nuss selbst knackt +++**********Weiterführende Quellen zu dieser Folge:SRT-H: A hierarchical framework for autonomous surgery via language-conditioned imitation learning, Science Robotics, 09.07.2025Geteilt, gerecht, zufrieden? Aufteilung von Hausarbeit in Beziehungen, Bundesinstitut für Bevölkerungsforschung, 09.07.2025Unlock the Walnut: How a Pectin-Rich Suture Tissue and Moisture-Driven Crack Formation Induce Shell Splitting and Facilitate Seed Germination, Advanced Functional Materials, 26.06.2025Nanoplastic concentrations across the North Atlantic, Nature, 09.07.2025Do turtles get cancer?, BioScience, 09.07.2025Alle Quellen findet ihr hier.**********Ihr könnt uns auch auf diesen Kanälen folgen: TikTok und Instagram .

Sir Peter Jackson is backing an ambitious project effort to bring back the Moa from extinction, and it is being led by Ngāi Tahu, Canterbury Museum, and Colossal Biosciences. Chief executive and co-founder Ben Lamm spoke to Ingrid Hipkiss.

Nick Johnston, a former biotech banker and entrepreneur, founded Alis Biosciences to solve one of the biggest challenges that every biotech might face on its road – how to maximize shareholders' value when a public-listed company loses market confidence? Alis creates a safety netfor shareholders by giving the trapped capital back and supporting the company with promising science to get back on track. Since its launch in 2025, Alis has identified over 300 small-cap biotech companies representing nearly $30 billion in underutilized capital, and has already completed successful take-private deals that delivered over 90% of uncommitted cash back to investors - faster and more efficiently than traditional liquidation processes. In this episode, you will hear about:Why Nick started Alis Biosciences, and how his background in healthcare banking shaped the model.How stagnation in capital markets leaves early-stage biotech companies in limbo and how Alis offers an innovative path forward.Why it still makes sense to invest in new science, and how Alis distinguishes between value traps and scientific opportunity.

"It's not a brute force approach. It's a cleverness-based approach. It's a new kind of information that lets us do new things." Host Jon Chee sits down with Ivan Liachko, founder and CEO of Phase Genomics, to unpack how clever, constraint-driven science turned a scrappy, bootstrapped lab into a genomics powerhouse. Ivan explains how their breakthrough technology—capturing the physical proximity of DNA—opened new frontiers in genome assembly, microbiome discovery, and cancer diagnostics, all propelled by a lean, scientist-led team and organic growth. The episode dives into Phase's evolution into a data-driven research leader, its focus on non-dilutive funding over venture capital, and its vision for clinical impact and therapeutic spinouts—all fueled by a passion for unlocking powerful new biological information.

For this episode of BioScience Talks, we're joined by Olivia del Giorgio, at McGill University Department of Geography, in Montreal, Quebec, María Piquer-Rodríguez, at the Institute of Geographical Sciences, at Freie Universität, Berlin, Germany, and Silvia Lomáscolo, at the Institute of Regional Ecology at University of Tucumán and CONICET, in Argentina. They were here to discuss their recent BioScience Viewpoint "Systemic Sexism in Academia - An Early Career Viewpoint."

For this episode of BioScience Talks, we're joined by Dr. Patt Finnerty, a postdoctoral research fellow in the Global Ecology Lab at the University of Sydney. We discussed his recent BioScience article, Urban Rewilding to Combat Global Biodiversity Decline. More information on Writing for Impact and Influence can be found here. 

Just about the hottest thing in longevity science right now is partial reprogramming - using Yamanaka factors to rewind the biological clock in our cells. Billion-dollar giants like Altos, Retro and New Limit are betting on it.But in this episode a far smaller player, Shift Bioscience, argues that the field may be looking in the wrong place. CEO Daniel Ives explains how his team used AI-powered virtual cells to uncover a single gene that seems to match OSK-level rejuvenation without the tumor risk that haunts classical reprogramming - and why their just-released data could change the game for aging research.

For the past two years, Jord BioScience has studied five microbial leads in soybean seed treatments to identify biological ingredients that can spur emergence, plant health and yield. Brownfield's Brent Barnett recently sat down with Andrea Arias, Vice President of Data Science & Crop Testing with Jord BioScience to learn more about the trials and the company.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Michael Ringel is the Chief Operating Officer of Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Michael became COO of Life just a few months ago, but he's been advising the company since 2018. Prior to this year, he was managing director and senior partner at Boston Consulting Group (BCG), where over a 25-year career he focused on R&D and innovation initiatives across the private sector and government. He earned his PhD in biology at Imperial College London and a JD from Harvard Law, and has become an active and highly respected member of the global longevity biotech community.In this episode, Chris and Michael explore Life Biosciences' groundbreaking approach to partial epigenetic reprogramming - the "holy grail" technology that could transform how we age at cellular, tissue, and organism levels. They discuss how this approach taps into the same biology that makes babies young, Life's lead therapeutic candidate ER-100 for eye diseases, and the "pipeline in a pill" concept at the core of the geroscience hypothesis: the idea that enable single interventions based on longevity science could treat multiple age-related diseases simultaneously.The Finer Details:The biology behind partial epigenetic reprogramming and how it differs from full reprogramming to pluripotencyWhy Michael considers partial reprogramming the "holy grail" of longevity interventionsLife Biosciences' lead candidate ER-100 for glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy)The innovative inducible system that allows the therapy to be turned on and off with doxycyclineWhy the eye represents an ideal starting point for reprogramming therapiesThe "pipeline in a pill" concept and geroscience hypothesis - how single interventions could treat multiple age-related diseasesParallels between the emerging longevity field and the massive GLP-1 drug market that many pharma companies missedThe role of philanthropic investment in advancing fundamental longevity researchEvolutionary theories of aging and why aging should be easily manipulableTimeline expectations for moving from single disease treatments to whole-body rejuvenationLinksLife Biosciences company websiteMichael Ringel's ARDD talk

Karl and Erum are joined by Dr. Ashley Beckwith, Founder & CEO of Foray Bioscience, for a wide-ranging conversation on the future of biomaterials and the emerging role of plant culture in shaping it. Ashley unpacks how Foray is pioneering new approaches to growing materials directly from plant cells, redefining how we produce, restore, and preserve biological resources. The episode explores the untapped potential of plant culture in bioproduction, ecosystem restoration, and biodiversity preservation when applied with care and intention. Ashley shares her path from growing up in Colorado to pursuing mechanical engineering and bioengineering, and how that interdisciplinary foundation ultimately led her to start Foray. Throughout the conversation, Ashley describes how Foray is building the foundational infrastructure for plant culture. The company develops core capabilities from the ground up and then partners with others to scale and specialize applications. This platform-based approach reflects Foray's belief that unlocking the full potential of plant systems requires a collaborative ecosystem rather than the efforts of a single company.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 - Kicking Off with a Big Question: Can We Rebuild Nature from the Cell Up?00:00:15 - Summer Vibes and Bio Talk: Memorial Day Weekend Catch-Up00:00:46 - Synbio Beta Sparks: The Pulse of Next-Gen Biotech00:02:27 - Argentina to IndieBio: The Unstoppable Founders You Need to Know00:04:01 - Biotech Gets Corporate: The Rise of Strategic Venture Funds00:05:11 - Deal Flow & Discovery: HC Wainwright's Biotech Bash00:08:18 - Brooklyn Bio Buzz: A Night Out with the Community00:10:24 - From the Explorers Club to Seed Vaults: Sci-Fi Meets Soil00:11:22 - Meet Dr. Asheley Beckwith: Engineering the Future of Fashion with Cells00:27:35 - Biology Meets Ecology: How Engineered Plants Could Aid Conservation00:30:12 - Sci-Fi to Soil: Fabricating Seeds for Extinct Ecosystems00:32:21 - The Wild Frontier: Overcoming the Barriers in Plant Cell Cultivation00:45:52 - Nature Meets Code: Using AI to Unlock the Secrets of Plants00:50:20 - Imagining Tomorrow: The Vision Behind ForayBio's Living Materials00:51:50 - Full Circle: Final Reflections from the Edge of BiodesignLinks and Resources:⁠Foray BiosciencesSF500 (Argentinian Global Venture Fund)Syensqo Corporate Venture FundH.C. WainwrightUniversity of Vermont - Dr. Steve KellerUniversity of Maryland - Dr. Matt Fitzpatrick⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Topics Covered: biomanufacturing, cell free biomanufacturing, enzymes, nutraceuticals, biotech, pharmaceuticals, AI, spinoutsHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: groweverything@messaginglab.comMusic by: NihiloreProduction by: Amplafy Media

Dr. Quyen Nguyen, CEO and Founder of Alume Biosciences, is developing fluorescent-guided precision surgery technologies that enable surgeons to visualize critical structures, such as nerves, blood vessels, and tumor margins, more clearly during procedures. Alume is developing fluorescent dyes and imaging systems to support this approach, building on work by Roger Tsien who won the Nobel Prize for fluorescence. This technology has the potential to enable more complex surgical procedures to be performed safely in brain, head, neck, and abdominal surgeries and has the promise to transform surgery. Quyen elaborates, "I first met Roger Tsien Nobel Laureate for his work in fluorescence, in 2001. I had worked with green fluorescent protein, one of the things that he was working on for fluorescence, and he ultimately was awarded the Nobel Prize for fluorescence. And I asked him, ‘Roger, is there a way we can make nerves fluorescent in patients? We certainly have that in research, but surgeons don't have this tool now.' And he said, ‘What, no one's done that yet?' And so that's the beginning of our story together. I see that the use of fluorescence is going to be transformative in the field of surgery. Who wants to turn off the light and see if surgeons can see and operate in the dark? So I feel like fluorescence is just another level of light that allows you to see structures more precisely." "Of course, you want to see structures more precisely so you can continue to carry on your work, tumor resection, reconstructive surgery, or any other procedures that patients are undergoing. Of course, you want to see tumor margins more clearly. Of course, you want to see arteries and veins and so forth. Of all the structures that we work on, I would say that nerves are considered the holy grail of surgery, partly because they're so delicate. One or two millimeters can take away somebody's ability to have urinary continence or erectile function or the ability to smile."   #AlumeBiosciences #FluorescentGuidedSurgery #PrecisionSurgery #HeadNeckSurgery AlumeBiosciences.com Download the transcript here

Dr. Quyen Nguyen, CEO and Founder of Alume Biosciences, is developing fluorescent-guided precision surgery technologies that enable surgeons to visualize critical structures, such as nerves, blood vessels, and tumor margins, more clearly during procedures. Alume is developing fluorescent dyes and imaging systems to support this approach, building on work by Roger Tsien who won the Nobel Prize for fluorescence. This technology has the potential to enable more complex surgical procedures to be performed safely in brain, head, neck, and abdominal surgeries and has the promise to transform surgery. Quyen elaborates, "I first met Roger Tsien Nobel Laureate for his work in fluorescence, in 2001. I had worked with green fluorescent protein, one of the things that he was working on for fluorescence, and he ultimately was awarded the Nobel Prize for fluorescence. And I asked him, ‘Roger, is there a way we can make nerves fluorescent in patients? We certainly have that in research, but surgeons don't have this tool now.' And he said, ‘What, no one's done that yet?' And so that's the beginning of our story together. I see that the use of fluorescence is going to be transformative in the field of surgery. Who wants to turn off the light and see if surgeons can see and operate in the dark? So I feel like fluorescence is just another level of light that allows you to see structures more precisely." "Of course, you want to see structures more precisely so you can continue to carry on your work, tumor resection, reconstructive surgery, or any other procedures that patients are undergoing. Of course, you want to see tumor margins more clearly. Of course, you want to see arteries and veins and so forth. Of all the structures that we work on, I would say that nerves are considered the holy grail of surgery, partly because they're so delicate. One or two millimeters can take away somebody's ability to have urinary continence or erectile function or the ability to smile."   #AlumeBiosciences #FluorescentGuidedSurgery #PrecisionSurgery #HeadNeckSurgery AlumeBiosciences.com Listen to the podcast here

For today's episode, we are joined by Thilina Surasinghe, Professor at Bridgewater State University in the Department of Biological Sciences, Kunwar Singh, Senior Geospatial Scientist at AidData and affiliate faculty at the Center for Geospatial Analysis, at the College of William & Mary, and Amy Frazier, Professor and the Jack and Laura Dangermond Chair of Conservation Science at the University of California, Santa Barbara, in the Department of Geography. They joined us to discuss their BioScience article about the promise that drone technology presents for undertaking biodiversity and conservation fieldwork. 

Colossal Laboratories & Biosciences: https://colossal.com Guests today: Dr. Beth Shapiro and Matt James. _______________________________________ If you appreciate my work and would like to support it: https://subscribestar.com/the-saad-truth https://patreon.com/GadSaad https://paypal.me/GadSaad To subscribe to my exclusive content on Twitter, please visit my bio at https://twitter.com/GadSaad _______________________________________ This clip was posted on May 5, 2025 on my YouTube channel as THE SAAD TRUTH_1850: https://youtu.be/jlfkuKSurcw _______________________________________ Please visit my website gadsaad.com, and sign up for alerts. If you appreciate my content, click on the "Support My Work" button. I count on my fans to support my efforts. You can donate via Patreon, PayPal, and/or SubscribeStar. _______________________________________ Dr. Gad Saad is a professor, evolutionary behavioral scientist, and author who pioneered the use of evolutionary psychology in marketing and consumer behavior. In addition to his scientific work, Dr. Saad is a leading public intellectual who often writes and speaks about idea pathogens that are destroying logic, science, reason, and common sense.  _______________________________________

Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes."  #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Download the transcript here

Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes."  #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Listen to the podcast here

Bioscience breakthroughs are transforming lives in Central Ohio. From cutting-edge gene therapies to world-first medical devices, the region's life sciences sector is booming—and saving lives. This week's Columbus Metropolitan Club forum brings together scientific leaders and business innovators to explore how research, investment, and clinical development are coming together to power the next generation of healthcare innovation.  Featuring:  Dr. Frank Agbogbo, Vice President of Process Development, Forge Biologics  Dr. Erandi De Silva, Investment Partner, Drive Capital  Dr. Louise Rodino-Klapac, Executive Vice President, Head of R&D, and Chief Scientific Officer, Sarepta  Robin Sears, President and CEO, LENTECHS  The host is Tyler Allchin, Managing Director, Healthcare, JobsOhio This forum was created in partnership with the 2025 COSI Science Festival, and was sponsored by: Armatus Bio, Battelle, Holder Construction, Ohio Life Sciences, The Ohio State University Wexner Medical Center, and Sarepta. The presenting sponsor of the CMC livestream was The Center for Human Kindness at the Columbus Foundation. Our livestream partner was The Columbus Dispatch. This forum was also supported by The Ellis. This forum was recorded before a live audience at The Ellis in Columbus' historic Italian Village on April 30, 2025. 

Alfredo, Leah and I chat about the recent de-extinction of dire wolves and what it means for the world. Sit back, relax, and enjoy some Happy Fools!Check out Leah's Art: https://www.leahck.com/Buy Trevor's Book: https://a.co/d/fMPgmFEJoin the Happy Fools Chatroom (Discord): https://discord.gg/hgCwDC6PEmail the Happy Fools @ happyfoolspodcast@gmail.com

A few weeks ago, Colossal Laboratories and Biosciences grabbed the world's attention when it announced the de-extinction of the Dire Wolf which last roamed the earth more than 12 thousand years ago, with the successful birth of three animals. Matt James, a long time zoo professional now serving as the company's Chief Animal Officer, discusses the science and technology behind the momentous announcement and the methodology's potential to help conserve extant but endangered species like red wolves. He also addresses some of the misinformation and misunderstanding about what this outcome has and has not achieved and where it   may lead in the future. Animal Care Software

What's the science behind a sweet tooth? James Gallagher explores whether sugar really can be addicted and what happens in our bodies when we want it and when we eat it. He's joined by Professor Susanne Dickson, who specialises in the neurobiology of appetite at the University of Gothenburg, and Professor James Brown from the School of Biosciences at Aston University.With Easter coming up, James meets dental hygienist and researcher Dr Claire McCarthy from King's College London in the BBC loos to get some top tips on keeping our teeth clean and gets a few pointers on where he could do with brushing up on his technique. Presenter: James Gallagher Producers: Tom Bonnett and Hannah Robins Assistant Producer: Anna Charalambou

S4:E167 First is The Weekly Update followed by an interview with Saksham Narang, Co-Founder and Vice President of Yuva Biosciences, a longevity startup focused on mitochondrial science to address aging-related conditions. Yuva has developed topical solutions for hair loss, skin wrinkles, and other aging conditions linked to declining mitochondrial function. The company's approach involves identifying molecules that can restore mitochondrial function, as demonstrated by their ingredient Y100. They produce Y100 in-house and then encapsulate it into a silica particle (Zpods) for extended release in the skin. They've had strong market adoption of their first OTC product through multiple channel partners and are developing several new products to expand their market penetration to Nutraceuticals for more systemic benefits. Yuva follows a partner licensing model where Yuva provides the encapsulated Y100 in bulk and the partner integrates Y100 into their existing product(s). (interview recorded 4.9.25)Listen to the All-In Pod Science Corner segment by David Friedberg on therapy for  mitochondrial dysfunction at 1:26:44Follow David and Paul: https://x.com/DGRollingSouth https://x.com/PalmettoAngel Connect On LinkedIn: https://www.linkedin.com/in/davidgrisell/ https://www.linkedin.com/in/paulclarkprivateequity/ We invite your feedback and suggestions at www.ventureinthesouth.com or email david@ventureinthesouth.com. Learn more about RollingSouth at rollingsouth.vc or email david@rollingsouth.vc.

On this episode of The Medical Alley Podcast, we have a conversation with Courtney Jones, Director of Commercial Development at Nu-Tek BioSciences.As the only completely animal-free peptone manufacturing site in the United States, Nu-Tek BioSciences is paving the way for sustainable and effective drug development. Courtney dives into the work Nu-Tek BioSciences is doing, its new manufacturing facility in Austin, MN, and the future of innovation in the biotech space.Send us a message! Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.

For this episode of BioScience Talks, we're joined by Marco Malavasi, plant ecologist and cartographer at the University of Sassari, in Italy. We discussed his recent BioScience article "Beyond crisis and grief: Rethinking conservation narratives," which serves as a guide to more productively communicating about—and thinking about—conservation in a rapidly changing world. 

Talking Aliens, UFOs, Biosciences and way weirder stuff Don't miss this one HEROparanormal.com

Professor Hank Greely is the Deane F. and Kate Edelman Johnson Professor of Law and Professor, by courtesy, of Genetics at Stanford University. He is also the Director of the Stanford Center for Law and the Biosciences. He talks about his career path into bioethics and ethical considerations for organoids, bodyoids, and embryo models. He also discusses the potential future of reproduction, including gametogenesis, ectogenesis, and genetic selection and editing of embryos.

Scientists have resurrected the long-extinct dire wolf after 11,000 years, sparking fierce ethical debates over the limits of genetic science.

*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.BEST OF: A new study warns and threatens that nearly all marine species will be extinct in 80 years. Conveniently Australian researchers and U.S. company Colossal Biosciences announced a plan to perform acts of necromancy and bring extinct species back from the dead. These include the Tasmanian tiger and even a wooly mammoth. A long time ago environmentalists were actually concerned about clean water, organic food, and leaving nature alone. Now the enviro-necromancers advocate for genetically modified animals, plants, and humans, and are eager to defy God in resurrecting creatures that do not even belong within our time period. Others are resurrecting dead pigs with 'sludge' pumped into their systems like a horror movie. This is truly an abomination of nature, a desecration of reality, wherein chimeras and hybrids usurp the natural order.-FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKMAIN WEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tst-radio--5328407/support.

*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.Colossal Biosciences has announced the successful resurrection of a set of Dire Wolves that have officially been extinct for 10-13,000 years. Time Magazine reported how the company can now “summon back species from the dead,” which “could prevent existing but endangered animals from slipping into extinction themselves.” Colossal Biosciences plans to birth a Mammoth by late 2028, having already in March announced it had copied mammoth DNA to create a woolly mouse,” which is admittedly a “chimeric critter.” In other words, as with the dire wolves, it's a mix of various pieces merged into one, i.e., it's a manmade creation. As Time reports, the company “rewrote the genetic code of the common gray wolf to match it [dire wolf], and, using domestic dogs as surrogate mothers,” resurrected the dead. Since April is the anniversary of the founding of the city of Rome in roughly 753 BCE it's all the more interesting that the company name their wolves after Romulus and Remus. One question is left unaddressed among the spectacle, magic, science, and obvious questions of morality or playing god: how do we define extinction or endangered. It's simple; the International Union for Conservation of Nature (IUCN), which once defined the former term as an animal not spotted in 50 years, now says an animal is extinct if there is “no reasonable doubt that the last individual member has died.” Better yet, these observations are often made not by the IUCN, but by citizens, as is common for bird watchers. The conservation status of each animal, plant and fungi species is compiled by the IUCN in what is called the "Red List,” which has over 41,000 species. And it is this arbitrary list which gives moral licensing and justification to those like Colossal Bioscences.  -FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKMAIN WEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tst-radio--5328407/support.

Guest: Dr. Shi En Kim Fungi are everywhere—from forests to deserts to cities to Star Trek! Science journalist Dr. Shi En Kim beams back aboard to talk about some of the latest developments in fungal research. "Can Fungi Save This Endangered Hawaiian Tree?" by Shi En Kim for Smithsonian Magazine: https://www.smithsonianmag.com/science-nature/can-fungi-save-this-endangered-hawaiian-tree-180985171/ "Why scientists are enlisting fungi to save endangered plants" by Shi En Kim for Knowable Magazine: https://knowablemagazine.org/content/article/food-environment/2025/mycorrhizal-fungi-help-save-endangered-plants-ecosystems "Biocrusts: The secret world living at the surface of drylands" by Shi En Kim for BioScience: https://academic.oup.com/bioscience/advance-article/doi/10.1093/biosci/biae119/7927803 "The Netherlands' Surprising Bus Stop Bounty" by Shi En Kim for bioGraphic: https://www.biographic.com/the-netherlands-surprising-bus-stop-bounty/ Follow us on Bluesky! Mike: https://bsky.app/profile/miquai.bsky.social Kim: https://bsky.app/profile/goesbykim.bsky.social

What happens when your own health journey leads you to discover groundbreaking wellness solutions? In this episode of #TheLongevityPodcast, Dr. Jen sits down with Dr. Kim Catherine Grom, a certified IHT wellness practitioner, licensed coach, and nutrition advisor. Dr. Kim shares her battle with late-stage Lyme disease and toxic mold exposure, which led her to seek alternative healing methods beyond traditional medicine. Through her practice, Bioscience for Believers, she now helps others using bio-scans and frequency testing to support wellness without venturing into new age or mysticism. This conversation is a deep dive into resilience, faith, and integrative health solutions that can transform lives.Dr. Kim Catherine Grom is a certified IHT wellness practitioner, licensed coach, and nutrition advisor. After battling late-stage Lyme disease and toxic mold exposure, she discovered alternative healing methods that transformed her health. Through Bioscience for Believers, she now helps others find balance using bio-scans and frequency testing.Facebook:https://www.facebook.com/kimcgrom#Instagram:https://www.instagram.com/kimgrom/Linkedin: https://www.linkedin.com/in/drkimgrom/Website: https://www.lifeconnectionswellness.com/PODCAST Thank you for listening please subscribe and share! - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Shop supplements: https://healthybydrjen.shop/ CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites WATCH THIS:https://www.youtube.com/watch?v=2lSyAFy5U4U&list=PLaDiqj0yz1eeCOATXPoUDt8HEJxz1_lfW - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FOLLOW ME: Instagram :: https://www.instagram.com/integrativedrmom/ Facebook :: https://www.facebook.com/pflegmed Tik Tok :: https://www.tiktok.com/@integrativedrjen YouTube :: https://www.youtube.com/@integrativedrmom - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not spons...

Synopsis: Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of the biggest challenges in biotech. With four ongoing Phase 1 trials in lymphoma, multiple myeloma, AML, and lupus, Caribou is leading the charge in making CAR T therapies more scalable, accessible, and cost-effective. Rachel also discusses Caribou's journey from a private startup to a publicly traded company, the role of strategic partnerships like Pfizer's equity investment, and how biotech companies can navigate today's uncertain funding landscape. She reflects on lessons from co-founding Caribou at just 26, the evolution of biotech entrepreneurship, and why raising more capital than you think you need is crucial. Plus, she shares her perspective on leadership, industry trends, and the importance of diversity in biotech, as seen during JPMorgan's ‘Pink Tuesday' movement. From cutting-edge science to strategic decision-making, this episode is packed with insights for biotech professionals, investors, and anyone fascinated by the future of gene editing and cell therapy. Biography: Rachel is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company's inception in 2011. Rachel is an inventor on patents and patent applications covering multiple CRISPR-based technologies, and has co-authored several scientific papers in high-impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. She serves on the board of directors for Biotechnology Innovation Organization (BIO). Rachel earned an AB in biological sciences from Harvard College and a PhD in molecular and cell biology from the University of California, Berkeley.

Research estimates the global animal health market to be roughly $8 billion, a number analyst firm Grand View Research expects to grow at a 10% compounded annual growth rate through 2030. Much of that growth will be driven by biotechnology. Dr. Todd Zion, CEO and founder of Akston Biosciences, joins this week to help understand what is happening in the biotech markets, specifically as it relates to companion animal innovation. We get into: Where the market sits today and how it is evolving Akston Biosciences' 2024 partnership announcement with Purdue University's College of Veterinary Medicine focused on a therapeutic for canine oncology His approach to animal health innovation through precision proteins creating affordable, effective treatments for companion animals What sits in the Akston Biosciences pipeline currently and the company's approach to cost-effectiveness while also staying innovative Todd's past work in human health, how he sees two sides – animal and human health – coming together to push innovation further, faster The regulatory hurdles faced by both human and animal health innovators that delay getting safe, effective treatments to market A big need for more risk capital coming into the animal health innovation market

Research estimates the global animal health market to be roughly $8 billion, a number analyst firm Grand View Research expects to grow at a 10% compounded annual growth rate through 2030. Much of that growth will be driven by biotechnology. Dr. Todd Zion, CEO and founder of Akston Biosciences, joins this week to help understand what is happening in the biotech markets, specifically as it relates to companion animal innovation. We get into:  Where the market sits today and how it is evolving Akston Biosciences' 2024 partnership announcement with Purdue University's College of Veterinary Medicine focused on a therapeutic for canine oncology His approach to animal health innovation through precision proteins creating affordable, effective treatments for companion animals What sits in the Akston Biosciences pipeline currently and the company's approach to cost-effectiveness while also staying innovative Todd's past work in human health, how he sees two sides – animal and human health – coming together to push innovation further, faster The regulatory hurdles faced by both human and animal health innovators that delay getting safe, effective treatments to market A big need for more risk capital coming into the animal health innovation market  

On this episode of the Somewhat Frank Podcast, Frank Gruber (X and IG: @FrankGruber), John Guidos (IG: jgoodtimes83), and Simon Kahan (IG: @simonkahan) discuss the following topics:   We are hosting the Established House in Austin on Friday, March 7th, with a couple of featured conversations, a barista spinning our delightful lattes and teas and lots of opportunities to connect with one another. If you'll be in Austin, please join us! RSVP at: est.us/house25    AI Is Changing How Silicon Valley Builds Startups - The traditional Silicon Valley model of heavy fundraising and large headcounts is being replaced by AI-driven efficiency, with companies like Anysphere and ElevenLabs reaching $100M revenue with under 50 workers. Also, here is Frank's take on it: https://www.linkedin.com/feed/update/urn:li:activity:7299885251869196288/    Mice have been genetically engineered to look like mammoths - Colossal Biosciences genetically engineered mice with mammoth-like fur by altering up to five genes, though only one matches the mammoth genome exactly. Here are some more thoughts on the animal/human hybrid topic: https://www.scientificamerican.com/article/japan-approves-first-human-animal-embryo-experiments/   Digg is coming back, thanks to its founder Kevin Rose — and Reddit's success - Digg is relaunching with Kevin Rose as chair, Alexis Ohanian as an adviser, and Justin Mezzell as CEO, aiming to revive its “homepage of the internet” legacy.   A Private Space Mission Just Successfully Landed on the Moon for the First Time - Firefly Aerospace's Blue Ghost lunar module became the first private company's lander to successfully touch down on the moon, landing on March 2, 2025.   We also upload our episodes to YouTube in video format so you can see us now. Check it out on Established YouTube, where you can subscribe to get updates when we drop a new episode at: https://soty.link/ESTYouTube    As always, thank you for listening, and feel free to reach out and let us know what you think at: somewhatfrank@est.us 

Discover the incredible engineering and visionary potential of Bernal Spheres, futuristic space habitats designed to sustain human life in the stars.Watch my exclusive video Big Alien Theory https://nebula.tv/videos/isaacarthur-big-alien-theoryGet Nebula using my link for 40% off an annual subscription: https://go.nebula.tv/isaacarthurGet a Lifetime Membership to Nebula for only $300: https://go.nebula.tv/lifetime?ref=isaacarthurUse the link gift.nebula.tv/isaacarthur to give a year of Nebula to a friend for just $30.Visit our Website: http://www.isaacarthur.netJoin Nebula: https://go.nebula.tv/isaacarthurSupport us on Patreon: https://www.patreon.com/IsaacArthurSupport us on Subscribestar: https://www.subscribestar.com/isaac-arthurFacebook Group: https://www.facebook.com/groups/1583992725237264/Reddit: https://www.reddit.com/r/IsaacArthur/Twitter: https://twitter.com/Isaac_A_Arthur on Twitter and RT our future content.SFIA Discord Server: https://discord.gg/53GAShECredits:Megastructures: The Bernal SphereEpisode 485; February 6, 2025Written, Produced & Narrated by: Isaac ArthurEditors: Ludwig LuskaGraphics: Bryan Versteeg, Fishy Tree, Jeremy Jozwik, Udo SchroeterSelect imagery/video supplied by Getty Images Music Courtesy of Epidemic Sound http://epidemicsound.com/creatorPhase Shift, "Forest Night"Chris Zabriskie, "Unfoldment, Revealment", "A New Day in a New Sector"Stellardrone, "Billions and Billions"See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.